Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

08 clinical trials for lorcaserin, APD125 and APD791. It also assumes continued progress with Arena's earlier stage programs. Arena expects to end 2008 with approximately $160 million in cash, cash equivalents and short-term investments and assumes common stock will be issued in connection with the conversion or redemption of outstanding shares of its series B redeemable convertible preferred stock, including any that may be redeemed on the series B-1's December 2008 mandatory redemption date. If Arena partners any of its later stage programs, it would expect that its year-end cash, cash equivalents and short-term investments would be higher.

Scheduled Earnings Call

Arena will host both a conference call and webcast to discuss the fourth quarter and full year 2007 financial results and to provide 2008 financial guidance and a corporate update today, Wednesday, February 27, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Jack Lief, President and Chief Executive Officer and Robert E. Hoffman, Vice President, Finance and Chief Financial Officer will host the conference call.

The conference call may be accessed by dialing 866.356.4281 for domestic callers and 617.597.5395 for international callers. Please specify to the operator that you would like to join the "Arena Fourth Quarter 2007 and Full Year Earnings Call." The participant code for the call is 19957700. The conference call will be webcast live under the investor relations section of Arena's website at http://www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Upcoming Corporate Presentations

Arena is currently scheduled to present at the following investment and industry conferences through May 2008:

-- Cowen 28th An
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Tropical birds waited for land crossing between North and South America: UBC study 2Germany starts its part in the International Cancer Genome Project 2Germany starts its part in the International Cancer Genome Project 3Germany starts its part in the International Cancer Genome Project 4Top Healthcare Magazine Awards Carefx Client 2009 IT Project of the Year 53045 1Top Healthcare Magazine Awards Carefx Client 2009 IT Project of the Year 53045 2Top Healthcare Magazine Awards Carefx Client 2009 IT Project of the Year 53045 3Hospira Reports Second Quarter 2009 Results 53042 1Hospira Reports Second Quarter 2009 Results 53042 2Hospira Reports Second Quarter 2009 Results 53042 3Hospira Reports Second Quarter 2009 Results 53042 4Hospira Reports Second Quarter 2009 Results 53042 5Hospira Reports Second Quarter 2009 Results 53042 6Hospira Reports Second Quarter 2009 Results 53042 7Hospira Reports Second Quarter 2009 Results 53042 8Hospira Reports Second Quarter 2009 Results 53042 9Hospira Reports Second Quarter 2009 Results 53042 10Hospira Reports Second Quarter 2009 Results 53042 11Hospira Reports Second Quarter 2009 Results 53042 12Hospira Reports Second Quarter 2009 Results 53042 13Hospira Reports Second Quarter 2009 Results 53042 14Hospira Reports Second Quarter 2009 Results 53042 15Hospira Reports Second Quarter 2009 Results 53042 16Hospira Reports Second Quarter 2009 Results 53042 17Hospira Reports Second Quarter 2009 Results 53042 18Hospira Reports Second Quarter 2009 Results 53042 19Hospira Reports Second Quarter 2009 Results 53042 20Hospira Reports Second Quarter 2009 Results 53042 21Hospira Reports Second Quarter 2009 Results 53042 22Hospira Reports Second Quarter 2009 Results 53042 23Hospira Reports Second Quarter 2009 Results 53042 24Hospira Reports Second Quarter 2009 Results 53042 25Hospira Reports Second Quarter 2009 Results 53042 26Hospira Reports Second Quarter 2009 Results 53042 27Hospira Reports Second Quarter 2009 Results 53042 28STAAR Surgical to Present at BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York 53040 1